Ozempic® lowers fasting and postprandial blood glucose by stimulating insulin secretion in a glucose-dependent manner.oneCurrently, the FDA has only specified approval to Wegovy, 2.4 mg, subcutaneous semaglutide, as an antiobesity medication.7 Sooner or later, it could be advantageous to investigate oral semaglutide as a weight loss medication, p